Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phenytoin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ginkgo Biloba on Phenytoin Elimination

NCT00011063
View directory record Official record
Conditions
Healthy
Interventions
Ginkgo Biloba
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

NCT03512756
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU
Drug
Lead sponsor
Tyme, Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

NCT06543043
View directory record Official record
Conditions
Not Determined
Interventions
Phenytoin, Itraconazole, sonrotoclax
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1Phase 2 Interventional

Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer

NCT02796898
View directory record Official record
Conditions
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Interventions
SM88 (Cohort 1), SM88 (Cohort 2)
Drug
Lead sponsor
Tyme, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Lawrence, New Jersey • Garden City, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional Results available

Phenytoin and Multidose Activated Charcoal

NCT00823264
View directory record Official record
Conditions
Phenytoin Toxicity
Interventions
Activated Charcoal
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 17, 2026, 4:30 PM EDT
Withdrawn Phase 3 Interventional

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

NCT02726867
View directory record Official record
Conditions
Epilepsy, Status Epilepticus
Interventions
levetiracetam, lacosamide, Ketamine, Phenobarbital
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

NCT04845646
View directory record Official record
Conditions
Healthy, NAFLD
Interventions
ASC41, Itraconazole, Phenytoin
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Levetiracetam to Prevent Post-Traumatic Epilepsy

NCT01463033
View directory record Official record
Conditions
Epilepsy, Post-traumatic Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
Pavel Klein
Other
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

NCT04720664
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions
SM-88
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

NCT00281879
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

NCT04981704
View directory record Official record
Conditions
Healthy
Interventions
Poziotinib, Itraconazole, Phenytoin, Paroxetine
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

NCT06919991
View directory record Official record
Conditions
Healthy Participants
Interventions
Casdatifan, Itraconazole, Phenytoin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants

NCT06906809
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-16673, Itraconazole, Phenytoin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

NCT00612235
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine, Levetiracetam, Carbamazepine, No Intervention
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

NCT07824193
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion
Drug
Lead sponsor
Epygenix
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults

NCT06466473
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (Ascoli), Phenytoin (Vega Baja)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AED/Statin Interaction Study

NCT00627575
View directory record Official record
Conditions
Epilepsy
Interventions
lamotrigine, atorvastatin, phenytoin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 17, 2026, 4:30 PM EDT
Completed No phase listed Observational

Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy

NCT00021866
View directory record Official record
Conditions
Epilepsy, Seizure, Cognition Disorders
Interventions
Differential Abilities Scale, Neuropsychological Testing
Behavioral
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)

NCT06719557
View directory record Official record
Conditions
Healthy
Interventions
Calderasib, Itraconazole, Phenytoin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

NCT05901714
View directory record Official record
Conditions
Healthy Participants
Interventions
Afimetoran, Phenytoin, Midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

NCT00610571
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
Oral Topotecan and Temodar
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 17, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures

NCT02088957
View directory record Official record
Conditions
Nonconvulsive Electrographic Seizures
Interventions
Brivaracetam intravenous solution, Brivaracetam oral tablets, Phenytoin intravenous solution, Phenytoin oral tablets
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Lexington, Kentucky • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 17, 2026, 4:30 PM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

NCT04229004
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Drug
Lead sponsor
Pancreatic Cancer Action Network
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 17, 2026, 4:30 PM EDT